Clinical Trial Detail

NCT ID NCT03935555
Title Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Samus Therapeutics, Inc.
Indications

myelofibrosis

Therapies

PU-H71

Age Groups: senior adult

No variant requirements are available.